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ABSTRACT
Gene therapy is a very challenging field, especially with new emerging genetic disorders.
Chitosan (CS), due to chitosan’s flexibility, biocompatibility, and biodegradability, has been of
interest in the world of gene therapy especially as researchers are gravitating towards non-viral
vectors due to the problems caused by viral vectors. Nevertheless, there are still issues regarding
solubility, cellular uptake of cargos being transported in vitro or in vivo, increased cytotoxicity
levels, as well as many other things that prevent chitosan from being an efficient gene delivery
agent. Here I present five derivatives of chitosan, which were all modified with either
triethylphosphonium butanamide (TEPB) or triethylammonium butanamide. In addition to the
TEAB and TEPB groups, only two were modified with methoxy-poly (ethylene glycol) or mPEG
units. The five derivatives are TEAB1-CS (24%of CS modified with TEAB), TEAB2-CS (40.6%
TEAB), TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG), TEPB-mPEG-CS (43% TEPB; 2.6%
mPEG), and TEPB-CS (43% TEPB). Cell proliferation and cytotoxicity assays were performed
for the derivatives using an XTT assay kit which demonstrated mild to no defects on the growth
of the cells. All derivatives were complexed with a TPST1-EGFP plasmid at a ratio of 10:1 and
were able to transfect HeLa cervical cancer cells with varying degrees of efficiency. TEABmPEG-CS and TEPB-mPEG-CS had low cell viability at 100 g/mL, however only TEPBmPEG-CS induce apoptosis in a dose dependent manner. TEAB2-CS and TEPB-CS had low
viability from the concentration ranges of 10-100 g/mL and both induced apoptosis in a dose
dependent manner. In particular, TEAB1-CS promoted viability at all treatment concentrations
and showed the highest transfection efficiency among all 5 CS derivatives, while TEAB-mPEGCS, TEPB-mPEG-CS, TEPB-CS, and TEAB2-CS exhibitited similar transfection efficiencies,
suggesting that TEAB1-CS would be the most effective for gene transfection.
KEYWORDS: chitosan nanoparticles, triethylammonium-butanamide chloride,
triethylphosphonium-butanamide chloride, gene therapy, degree of quaternization, N+/P- ratio,
P+/P- ratio, biopolymer cytotoxicity, pDNA transfection
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INTRODUCTION

Biological Characteristics of CS and Its Derivatives
Since its discovery in mid-1800s, chitosan has been used in tissue regeneration, wound
healing, cancer therapy, gene therapy, drug delivery, among many other things [1-7]. A table
summarizing many recent applications of chitosan and its derivatives is included here (Table 1).
Chitosan can be derived from chitin housed on the exoskeleton of insects and crustaceans, such
as lobsters, crabs, and shrimp [1, 2, 7]. Conversion of chitin to CS is shown in Figure 1. The
degree of acetylation in chitin is around 90%, while chitosan is a fully or partially N-deacetylated
derivative with a typical degree of deacetylation of more than 65%. Chitosan is comprised of
glucosamine and N-acetylated glucosamine units that are linked through - (1-4) glycosidic
linkages (Fig. 1) [8].

Figure 1. The conversion from chitin to chitosan through chitin deacethylation [1]. Chitin and CS
are polysaccharides made up of N-acetyl glucosamine and D-glucosamine functional groups.
Chitin has more N-acetyl glucosamine groups than chitosan. CS has three different functional
groups, two OH groups and one NH2 group that can be modified for many biological
applications.
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The glucosamine of chitosan has primary amine groups with pKa of 6.5, which allows the
biopolymer to only be soluble in acidic solution but not neutral or basic solution [5, 9]. The
activity of chitosan is influenced by Degree of Acetylation (DA) due to charge change upon
deacetylation. It was reported that chitosan with 25% DA had a lower antibacterial activity than
CS with 5% DA [1, 10]. Low acetylation degree constituted for higher positive charges per
molecule of chitosan, which is important for stability of the polyplex formed when the polymer
complexes with a gene or a drug [5].

Modification of OH and NH2 Functional Groups on CS
Chemical modification of CS can be used to attain derivatives with preferred properties,
and these modifications have proven to be safe for gene therapy usage. For instance, chitosanDNA complexes integrated into THP-1 leukemia cells did not stimulate the release of proinflammatory cytokines [11]. Chitosan has two types of reactive groups that can be modified: 1)
free amino groups on deacetylated units and 2) hydroxyl groups on acetylated or deacetylated
units such as the -OH groups on C-3 and C-6 carbons (Figure 1) [1, 2, 12]. Chitosan's cationic
property from the amino groups is a main advantage, especially in dealing with negative
phospholipids or nucleic acids. These NH2 groups can be protonated to NH3+ in an acidic
condition and as a result, these protonated NH3+ groups are able to form stable polymer
complexs with anionic counterparts such as nucleic acids [13, 14]. Along with these primary
amino functional groups, chitosan’s OH groups offer many biological applications via their
chemical alteration [1, 15, 16].

The N-alkylation reaction occurs on the C2-NH2 group because

this group is a stronger nucleophile than the OH group, and thus O-alkylation, which could occur
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at C3-OH or C6-OH, is less likely to occur. N-alkylated chitosan derivatives have shown
antibacterial and coagulation properties and have thus been used to prepare medical supplies
such as medical gauze. This type of derivative has also served as a surfactant for water
purification engineering as well [5]. Although O-alkylation is less likely to occur, the hydroxyl
group can be carboxylated by reacting with glyoxylic acid or chloroalkanoic acid. The
carboxylation reaction, which increases the solubility of chitosan in water, occurs at the C6-OH
group, allowing it to be dissolve in a pH greater than 7. Whereas carboxylation at the C3-OH
group is more difficult due to steric hinderance [5, 14].

Applications of Chitosan
Chitosan has been incorporated in the production of bandages due to their anti-bacterial
properties, as well as enzyme immobilization on solid surfaces and surface coating of enzymes,
which allows for reusability, thus promoting cost-effectiveness [17, 18]. Other applications of
chitosan include food preservation, as shown in a study that it was used for the promotion of crop
growth such as radishes. It has also been used to minimize water loss in field crops, enhance
enzyme activity in peanuts, and to prolong the storage of fruits by stimulating cellular defense
compounds [1]. However, there have been rare incidences by which chitosan produced
undesirable characteristics. For example, a study that was investigating the effects of chitosanbased gene therapy on amniotic fluid (in vitro) reported that while CS protected the plasmid
DNA from degradation it also formed aggregates in the amniotic fluid, thus meaning that CS can
pose a threat during fetal development [19].
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Gene Delivery Using Chitosan and Its Derivatives
Gene therapy is the delivery of genes into specific cells for therapeutic benefit and can
offer possible lasting treatment for cancer. A challenge for gene therapy is to design a carrier that
is effective in protecting the gene of interest from nucleases as well as efficient transfer to
targeted cells. Viruses are the most common vectors for gene therapy, although gene therapy
using viral vectors is associated with immunogenicity as well as rare cases of disease [20].
However, Due to its versatility, biodegradability, and safety, chitosan has recently been gaining
interest as a potential non-viral vector in the field of gene therapy. Additionally, stability in a
biological environment is a quality all ideal DNA/RNA delivery vectors should have. Chitosan
protect genetic material from being degraded by nucleases through CS-DNA polyplex formation.
In formation of the CS-DNA polyplex, the positively charged amine groups on chitosan interact
with the negatively charged groups on DNA/RNA in order to form a stable CS-DNA/RNA
polymer complex [2, 21, 22].
In 1995, the first ever non-viral gene delivery experiment using chitosan was performed
using TMC [23]. TMC is an ammonium quaternized chitosan derivative, first synthesized in
1986, and has been proven to have mucoadhesive properties. This derivative is synthesized by
addition of a trimethyl group to chitosan’s NH2 group. The process of synthesizing TMC
involves trimethylation of the primary amines of chitosan in alkaline solution. Kean et al.
measured the transfection efficiency of pGL3 luciferase plasmid-DNA using TMC and TMOs
(trimethylated oligosaccharides) at differing degrees of trimethylation (DTM) in MCF-7 breast
cancer and COS-7 monkey kidney fibroblast-like cell lines [24]. The authors found that the
transfection was cell dependent. Moreover, the results showed higher transfection efficiencies
with TMOs in both cell lines than most of the TMC derivatives. However, in the MCF-7 cell
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line, 93% TMC which was the TMC derivative with the greatest degree of trimethylation (93%
DTM) had the greatest transfection efficiency [24].
Nevertheless, TMC showed higher cytotoxicity compared to the unmodified chitosan.
Usually, caveats to TMC are related to its molecular weight (MW); a MW of 400 kDa displayed
high cytotoxicity, while 5 and 25 kDa TMC exhibited little to no toxicity.[1],45, 46, Research has
shown that the cytotoxicity is due to the positive charge of TMC which might be interacting with
the negatively charge cell membrane which could lead to cell membrane damage [1, 24, 25].
There are very few reports on the cellular uptake mechanisms of CS-DNA/RNA
polyplexes. To understand the cellular uptake of CS-pDNA polyplex, Hashimoto et al.
synthesized mannosylated chitosan (Man-C) with 5% and 21% degree of substitutions for use as
gene carriers into mouse peritoneal macrophages and COS7 cells, in order to understand the
cellular uptake of CS-pDNA polyplex [26]. The authors discovered that transfection with both
5% and 21% Man-C were better than unmodified chitosan in the macrophages, but in the COS7
cells, the carrier efficiency was greater with the 5% Man-C than 21% Man-C derivative [22, 26].
The Man-C derivative with 21% substitution might have been causing extracellular damage due
to 21% Man-C being more hydrophilic than the unmodified and 5% chitosans.
Additionally, a factor that affects gene therapy is the CS-nucleic acid N+/P- ratio. N+/Pratio is the ratio of positively charged amino group on chitosan to negatively charged phosphate
groups on nucleic acids [2]. N+/P- ratio influences the stability of the polyplex formation, the
transfection efficiency, and polymer-cell interactions [2]. A study comparing transfection
efficiencies of 6-amino-6-deoxy-chitosan (6ACT) at N+/P- ratio of 2.5 and chitosan-DNA at
N+/P- ratio of 5 and found that the 6ACT derivative was the better gene carrier. 6ACT-DNA and
CS-DNA complexes were also compared to polyethyleneimine (PEI) which had a higher N+/P-
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ratio, and the results showed that PEI had better transfection efficiencies than both complexes
[27]. High N+/P- ratio can lead to strongly formed polyplex through electrostatic interactions.
However, if the bond between the DNA and the polymer is too strong, this can prevent the
nucleic acid from being released once it arrives at its site of action, thus hindering the release of
the gene from the polymer complex [2, 28]. Additionally, an extremely low N+/P- ratio can
cause formation of aggregates which affect cell internalization, thus resulting in poor transfection
[22].
Another category of chitosan derivative used for gene delivery is thiolated chitosan.
Thiolated chitosan derivatives were discovered in the early 2000s, especially novel derivative in
which chitosan is conjugated to 4-thiobutylamidine (TBA), chitosan-TBA. Due to their cell
permeability and mucoadhesive properties, these types of derivatives show enhanced polymerDNA complex stability, and excellent gene delivery both in vivo and in vitro [29]. During
reducing conditions, breakage of the disulfide bonds lead to dissociation of the DNA being
delivered, whereas during oxidation, the disulfide bond formation in the thiolated chitosan is
favored, which leads to tight binding of DNA and a stable solid polyplex.
Finally, gene delivery must be safe for use in gene therapy. However there have been rare
incidences by which chitosan produced undesirable characteristics. A study that was
investigating the effects of chitosan-based gene therapy on amniotic fluid (in vitro) reported that
while CS protected the plasmid DNA from degradation it also formed aggregates in the amniotic
fluid [19]. CS can be chemically modified to attain derivatives with preferred properties, and
these modifications have been proven to be safe for gene therapy usage. The key is producing the
optimal modification. A study reported that chitosan-DNA complexes integrated into THP-1
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leukemia cells did not stimulate the release of pro-inflammatory cytokines. Nevertheless, TMC
showed higher cytotoxicity compared to the unmodified chitosan.
Usually, caveats to TMC are related to its molecular weight (MW); a MW of 400 kDa
displayed high cytotoxicity, while 5 and 25 kDa TMC exhibited little to no toxicity [1, 30, 31].
Research has shown that the cytotoxicity is due to the positive charge of TMC which might be
interacting with the negatively charged cell membrane, which could lead to cell membrane
damage. Thus, TMC with higher MW would have more positive charge than TMC with lower
MW and could cause more damage to the cell membrane [1, 24, 25]. In vitro hemolysis
experiments were performed using chitosan-TBA to evaluate its safety on red blood cells. The
derivative displayed a low hemolytic effect on the red blood cells which might have been
attributed to the change of the primary amine moieties into secondary amine groups after thiol
modification with TBA [1, 29]. Although some toxicity is observed with some chitosan
derivatives, some modification, or the degree of modification appear to ameliorate the toxic
effects and can be used to make safe and effective gene delivery tools.

Other Applications of Chitosan
Drug Delivery Using CS and Its Derivatives. Although chitosan has anticoagulant
properties and was involved in wound healing, it wasn’t until the late 1990s that the chitosan was
used as a drug delivery carrier. This is mainly due to chitosan’s solubility issues, which prevents
it from delivering the drug to biological systems [32]. Moreover, due to unmodified chitosan’s
pKa of 6.5 it is not a stable drug carrier. Drug delivery agents must be stable at physiological
pH. In order to overcome this problem, there have been many attempts to modify chitosan by
derivatizing the OH or NH2 groups on the polymer. Common types of modifications to make
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chitosan more biocompatible include quaternization, sulfonation, carboxymethylation, N- and Ohydroxyalkylation [13]. Examples of hydrophilic modifications to chitosan listed in this review
include quaternization using ammonium groups and N-modification with the succinyl group.
One study demonstrated the usage of N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan
chloride (HTCC) as a drug delivery agent for ribavirin, and the results showed an initial burst
release of the drug at increasing degree of substitution (Table 1) [3, 5, 15, 16]. As modified CS
derivatives are internalized via endocytosis, they are able to deliver therapeutic drugs into cells
without endangering these biologically active cargos [17, 32-34].

Table 1. Examples of chitosan, its derivatives, and their applications.
Chitosan Derivative
Low molecular

Application

Target /Cargo

Antibacterial/antioxidant

Superoxides,

weight chitosan

DPPH (2,2-

(LMWC)

diphenyl-1-

Discovery
Timeline
1993

References
[1]

picrylhydrazyl),
and H2O2 radicals
Chitosan; Chitosan-

Wound healing

Stimulate

soy; Chitosan-soy-

macrophage and

tetra ethyl ortho

attract neutrophil

silicate

to site of wound

1994

[1] [30] [32]

1994

[1] [46]

1995

[45] [46]

(Cht/soy/TEOS)
N-succinyl-chitosan

Drug delivery

Treatment for

(Suc-Chi)
Trimethyl chitosan

arthritis
Gene delivery

pDNA

(TMC)

8

N-benzyl sulfonate

Adsorbent

Removal of heavy

chitosan

1996

[1] [34]

metals and
pollutants

Table 1 continued. Examples of chitosan, its derivatives, and their applications.
Chitosan Derivative

Application

Target /Cargo

Discovery

References

Timeline
Collagen chitosan-

Tissue engineering

Attachment to

based matrices

1998

[26] [27] [28]

2000

[23] [26] [29]

bovine adrenal
chromaffin cells

Dextran sulfate (DS)-

Tissue regeneration, cell

Human smooth

chitosan

proliferation

muscle cell and
endothelial cells

PEG-Chitosan

Gene delivery

Survivin-siRNA

2001

[12]

Glycol-Chitosan

Gene delivery

Multi drug

2001

[12]

2001

[81]

2005

[18] [39] [41]

(Glycol-CS)

resistant 1
(MDR1)-SiRNA

Chitosan-coated

Gene delivery

Sequestosome I

polylactic acid
Palmitoyl chitosan

siRNA
Drug delivery

Subdermal and
oral drug delivery

Mannosylated

Gene delivery

pDNA

2006

[49] [50]

Drug and gene delivery

FD4 parcellular

2007-2008

[49]

chitosan (Man-C)
Chitosan-Nacetylcysteine (Ch-

marker, acyclovir

NAC)
PEGylated-TMC

Gene delivery

pDNA

2008

[45]

Gene delievery

DNA

2009

[82]

(PTMC)
Chitosan-betainates
(CsB)

9

N, O-carboxymethyl

Drug delivery

Chemotherapeutic

chitosan (N, O-CMC)
Trimethyl-chitosan-

2010

[1] [40] [42]

2010

[49]

drug curcumin
Gene delivery

pEGFP

cysteine (TMC-Cys)
Table 1 continued. Examples of chitosan, its derivatives, and their applications.
Chitosan Derivative

Application

Target /Cargo

Discovery

References

Timeline
Chitosan-

Gene delivery

siRNA delivery

hydroxybenxotriazole

and gene

(Chitosan-HOBT)

silencing

Chitosan-thioglycolic

2010

[35]

Gene delivery

pDNA

2011

[49]

N-sulfurfuryl

Anticoagulant,

Non-

2012

[1] [39]

chitosan

adsorbent

thrombogenic
2012

[1] [39]

2014

[3] [5] [16]

acid (Ch-TGA)

properties
N, O-sulfonated

Anticoagulant

Strong

chitosan

anticoagulant

N-(2-hydroxyl)

Drug delivery/gene

Anti-viral drug

propyl-3-trimethyl

delivery

ribavirin

Gene delivery

pDNA

2015

[83]

Antibacterial drug

Antibacterial drug

2016

[14] [51]

delivery

ciprofloxacin

[17][35]

ammonium chitosan
chloride (HACC)
2-acrylamido-2methylpropane
sulphonic acid
modified LMWC
Chitosan-lauric acid

against S. aureus
and E. coli

10

Double N-

Antibacterial/antioxidant

Scavenging

quaternized chitosan

ability against

(DQCS)

superoxides,

2018

[4]

DPPH, and
hydroxyl radicals
Table 1 continued. Examples of chitosan, its derivatives, and their applications.
Chitosan Derivative

Application

Target /Cargo

Discovery

References

Timeline
Single N-quaternized

Antibacterial/antioxidant

chitosan (QCS)

Scavenging

2018

[4]

ability against
superoxides,
DPPH, and
hydroxyl radicals

Modified chitosans such as TMC show promise results in the intranasal administration of
certain drugs and proteins, due to their cationic propertiesthat allow for complexation with the
drug of interest. Intranasal admistration allows for direct access to the brain, which has many
advantages such as rapid onset of action and fewer adverse effects [35]. Turabee et al. developed
a hydrogel made from pluronic F127 (PF127) in order to treat the malignant glioblastoma cell
line U87MG, using a murine model. They discovered that after addition of TMC to the PF127
hydrogel, delivery and release of the anticancer drug docetaxel (DTX) was much better
compared DTX alone or DTX encapsulated with PF127, in vitro. The authors were able to show
that PF127-TMC hydrogel was capable of tumor suppression, in vivo, with the delivery of DTX
[13, 36].
Moreover, in 1994, a patent was requested to use N-succinyl-chitosan or Suc-Chi
(originally developed in the late 1990s for wound dressing) as a treatment for arthritis. Suc-Chi
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exhibits low toxicity, is biocompatible, and can be retained for a long period of time in the body.
It has been used as a drug carrier and when conjugated with the chemotherapeutic drug
mitomycin C, it presented antitumor activity against many tumors (Table 1) [1]. Furthermore,
chitosan loaded with dopamine was proven to minimize cytotoxicity and used to facilitate
transport the dopamine across the blood brain barrier for Parkinson’s disease [22, 37, 38].
Research has shown that delivery of cargo such as hydrophobic drugs are problematic
due to their hydrophobic nature. Due to chitosan’s insolubility in hydrophobic solvents, its
ability to transport hydrophobic drugs is restricted. In order to resolve this limitation, researchers
have modified chitosan with hydrophobic groups such as pyridine, among many other groups, to
improve the ‘encapsulation efficiency’ of the hydrophobic cargo [13, 39]. Examples of
hydrophobic modifications include palmitoyl units and the carboxymethyl group. When chitosan
was substituted with palmitoyl units (degree of substitution 40-50%), its best drug release
characteristics were displayed, which proved that palmitoyl chitosan could be used in subdermal
and oral drug delivery applications (Table 1) [40-42]. The chitosan derivative, N, Ocarboxymethyl chitosan (N,O-CMC) nanoparticles was used to carry hydrophobic
chemotherapeutic drugs such curcumin (Table 1) [1, 43, 44]. Nevertheless, such hydrophobic
modification of chitosan polymer tend to have low reproducibility, proving that chitosan is not as
successful in delivering hydrophobic drugs [45]. Despite this, chitosan still serves as one of the
most effective drug delivery agents.
Chitosan-Coated Materials and Complexes. Chitosan and its derivatives have also
been used as encapsulating agents for proteins and glycans such as bovine serum albumin,
hemoglobin, and dextran due to their high affinity for the cell membrane [41]. Moreover, when
chitosan was used to coat PLGA (poly(lactic-co-glycolic acid)) microparticles containing the
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tetanus toxoid, CS improved the stability of the drug and PLGA by preventing degradation by
lysozyme. Furthermore, this CS-PLGA coating enhances the nasal transport of the drug due to
chitosan’s mucosal adhesion or mucoadhesive properties. Another study demonstrated that
conjugation of chitosan to poly(acrylic acid) (PAA), an anionic polyelectrolyte, was useful in the
delivery of gastric antibiotic drugs due to the chitosan-poly (acrylic acid (Ch-PAA) derivative
being stable under acidic conditions [41].
It is widely accepted that modified chitosans have chemical properties superior to
unmodified chitosan. However, unmodified chitosan has various favorable characteristics that
make them effective gene delivery agents such as biocompatibility, low cytotoxicity,
biodegradability, and stability when forming complexes [2]. Unmodified chitosan that was used
for the removal of organic matter such as algae, proved to be more efficient than t coagulating
inorganic compounds such as (Al2(SO4)3, KAl(SO4)2, Ca(OH)2). Chitosan was albe to remove
about 95% of algae from algae-containing waters [1]. Regardless of these characteristics,
unmodified chitosan has certain constraints, a main one being solubility. Chitosan is insoluble in
physiological pH, thus, it is necessary for modifications that make it easier to incorporate the CScoated materials and complexes into cells.
Tissue Engineering Applications Using CS Derivatives. Chitosan’s ability to be
refined into porous material is an excellent characteristic that is useful for tissue engineering
applications because it can be made into scaffold grafts for tissue engineering [30, 31, 46].
These scaffold grafts stimulates the regeneration of certain types of tissues such as bone tissue,
among many others. Tissue engineering using chitosan-based matrices in transplantation
procedures of bovine adrenal chromaffin cells was discovered in 1998 (Table 1) [47-49]. Since
then chitosan and its derivatives have been used in many tissue regeneration due to their low to

13

non-existent tissue toxicity, biodegradability, as well as peritoneal adhesion prevention [34].
Among such experiments is one study that reported that modification of chitosan with multiple
proteins such as collagen, gelatin, and albumin enhanced its biocompatibility. The results
demonstrated that a matrix made up of collagen modified chitosan attached more readily to the
cells than the other proteins (Table 1) [47]. Additionally, chitosan’s hydrophilic surface
promotes cell proliferation and adhesion much better than several synthetic polymers. Chupa et.
al reported the use of both heparin-CS and dextran sulfate (DS)-chitosan complexes to stimulate
cell proliferation and tissue regeneration of human endothelial cells and smooth muscle cells, in
vivo [30, 47, 50]. These type of experiments thus prove the potential of CS to be used in
scaffolds that enhance and promote cell and eventually tissue regeneration.
Wound Healing and Anticoagulant Properties of CS and Its Derivatives. Wound
healing using chitosan was first discovered in late 1980s-early 1990s [13, 51]. Studies have
shown that chitosan improves skin wound healing and facilitates re-epithelization. There have
been numerous articles investigating chitosan and its derivatives’ influence on peritoneal
adhesion formation. These studies demonstrated that as the degree of acetylation on chitosan
biofilms increased, cell proliferation and adhesion decreased [52]. Chitosan also reduces
inflammation at the wound site, and promotes dermal regeneration. Additionally, the biopolymer
has the capability to accelerate wound healing because it stimulates macrophages and attracts
neutrophils [1, 53, 54].
Research has shown that derivatives of CS substituted with sulfonate groups have high
anticoagulant activity due to their similarity with heparin, a common anticoagulant medication.
These sulfonated derivatives have no side-effects and are less expensive compared to heparin
and have in fact have replaced heparin in many pharmaceutical and clinical settings [1].
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Examples of such derivatives are N-Sulfofurfuryl chitosan, O-sulfonated chitosan, and N,Osulfonated chitosan. Amphoteric water-soluble chitosan derivatives such as N-sulfofurfuryl
chitosan and N-benzyl sulfonate chitosan, possess non-thrombogenic properties and can be used
for blood-coagulating applications. They have also been used in wastewater applications.[1]
N,O-sulfonated chitosan also showed strong anticoagulant activities by inhibiting thrombin
activity, as did O-sulfonated chitosan, which was reported to have excellent inflammation
inhibition activities (Table 1) [1]. These sulfonated chitosan derivatives are also used to remove
organic pollutants and heavy metals, such as Cd2+ , Zn2+ , Ni2+ , Pb2+ , Cu2+ , Fe3+ , and Cr3+
from industrial sewages and proved to remove these pollutants and heavy metals much better
than unmodified chitosan could (Table 1) [1, 55].
Antioxidant and Antimicrobial Properties of CS and CS Derivatives. In 1992,
chitosan was discovered to have antioxidant and antimicrobial properties in Japan by researchers
who were trying to investigate its effect on macrophage activation and antimicrobial activity
[56]. Derivatives of chitosan, especially low molecular weight chitosan (LMWC), have
displayed strong scavenging activity towards superoxides such as H2O2 and 2,2-diphenyl-1picrylhydrazyl (DPPH) radicals [1, 56]. A study measuring the antioxidant activity of
unmodified chitosan and two derivatives, double N-quarternized chitosan (DQCS) and single Nquarternized chitosan (QCS), demonstrated that DQCS had the best scavenging ability compared
to both unmodified CS and QCS in the presence of DPPH, hydroxyl radicals and superoxide
radicals [4].
Another way chitosan demonstrates its antioxidant properties is that it protects from
hypertrophy of adrenal glands (induced by LPS), prevents from shrinkage of the thymus,
changes of hormones, glycolysis and glycogenolysis activation, and lipid peroxidation in liver
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cells [1].

Sinha et al. investigated the antimicrobial activities of chitosan crosslinked with fatty

acids (lauric, stearic, and capric saturated fatty acids) as well as drug delivery of ciporoflaxacin
against S. aureus and E. coli. They discovered that the chitosan-lauric acid derivative and the
chitosan-lauric acid-ciporoflaxacin complex had inhibitory effects against the two microbes [57].
Additionally, when unmodified chitosan was complexed with lipopolysaccharide (LPS), it
inhibited cytokine production in macrophages (RAW 264.7) [1, 13, 57]. The CS-LPS complex
also led to more enhanced phagocytic activity of the macrophages than when the macrophages
were stimulated with LPS alone.

Limitations of Chitosan as a Non-Viral Vector and the Future of Chitosan
The derivatives aformentioned have demonstrated the various applications and versatility
of chitosan in many different fields. The potential for chitosan to serve as as a gene delivery
agent is based on its variability in the N+/P- ratio of the polyplex. However, modifications on
chitosan such as addition of thiol groups, quarternization on the amino groups, addition of
hydrophobic groups, addition of sulfono group, etc. Limitations of chitosan that impact drug and
gene delivery are due to pKa degree of acetylation and MW. High MW chitosan can lead to
unstable CS-DNA polyplex formation as well as problems with cellular uptake and release of the
nucleic acid into the cytoplasm [1, 21, 58, 59]. Although, DA and MW can become
advantageous in chitosan becoming a vector for drug and gene delivery, e.g. through
modification, other limitations include an increase in cytotoxicity as well as a reduction in gene
binding capacity when the biopolymer has been modified with a high degree of substitution [59].
Many of these derivatives have good characteristics such as high gene delivery capacity,
protection of cargo from lysozyme degradation, low cytotoxicity and solubility. Nevertheless,
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cytotoxicity could be caused by steric effects in N-substituted (quaternization of the amino
groups on chitosan) derivatives such as TMC which can be seen in many of the chitosan
derivatives [24, 25]. This could serve as a precaution to researchers as they investigate certain
degree of substitutions that would make chitosan a more efficient gene delivery vector. In order
for these derivatives to be efficient gene carriers, they must demonstrate excellence in these
characteristics. With this information, research should be geared towards using chitosan and its
derivatives in treating of genetic and autoimmune disorders, as more awareness about these
diseases is being brought to light.
Moreover, factors such as degree of deacetylation, ionic strength of the solution, and the
molecular weight influence the solubility of chitosan and its ability to be an efficient delivery
agent [16, 37]. Another limitation of chitosan include the inability to release therapeutic cargo
intracellularly after endocytosis when complexed with DNA, thus leading to a less efficient
delivery of DNA, in vitro [28, 60, 61]. Endo-lysosomal release of these genetic materials into
the cell is just as important as internalization in the cell [6, 60, 62, 63]. As these CS
nanoparticles are internalized via endocytosis, they can deliver drugs into the cytoplasm without
endangering these biologically active cargos.
Although chitosan has been used in various applications, there are very few gene
therapy-based studies using chitosan modified with ammonium or phosphonium salts such as
triethylphosphonium butanamide (TEPB) and triethylammonium butanamide (TEAB).
Phosphonium-containing polymers were reported to have fewer toxic effects on HeLa cells
following transfection with gWiz-Luc plasmid. The study reported cell viability higher than 70%
with phosphonium derivatives and less than 60% viability with their ammonium analogues [64].
This is due to the charge distribution on adjacent carbon groups attached to the phosphonium
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cation. Due to nitrogen’s high electronegativity compared to carbon, the positive charge of
carbon is distributed on adjacent carbons, which results in a negative charge on the nitrogen
atom. Some of these positive charges on the adjacent carbons affect the cell membrane by
interacting with the negative components of the cell membrane. This interaction can then
endanger the cell and cause toxicity. Whereas, phosphorus has the opposite charge distribution
due to it being more electropositive than carbon, thus resulting it a negative charge on the
adjacent carbons and a overall positive charge on the phosphorus. The sizes of the cationic
polymers as well as charge densities influence the binding affinity of this biopolymers. Meaning
that such phosphonium polyelectrolytes are more cationic than the ammonium-containing
derivatives thus allowing for more effective binding of DNA [64]. Therefore, the aim of the
present work is to determine if these chitosan derivatives can be used as efficient gene delivery
vectors [8, 59].
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HYPOTHESIS

In this project I tested the transfection efficiency of two types of chitosan derivatives,
chitosan containing triethylphosphonium butanamide (TEPB) groups and chitosan containing
triethylammonium butanamide (TEAB) groups in the HeLa cervical cancer cells. As mentioned
above, phosphonium polyelectrolytes have fewer cytotoxic effects on HeLa cells than
ammonium analogues. In addition, PEGylation of biopolymers has been reported to inhibit
apoptotic effects because the PEG units reduce cytochrome c, which promotes apoptosis, and
also improve mitochondrial function [65]. Foremost, I hypothesized that the two TEPB derived
CS polymers would have limited to no cellular toxicity compared to the three CS derivatives
containing TEAB. This part of the project was tested using a XTT assay cell viability kit.
Following, an apoptosis kit was used to further quantify the effects of the derivatives. I
hypothesized that the TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) derivative would not induce
apoptosis, in comparison to the other four derivatives used (TEAB1-CS (24% TEAB), TEAB2CS (40.6% TEAB), TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG), and TEPB-CS (43%
TEPB)). Third, I hypothesized that both TEPB-CS (43% TEPB) and TEPB-mPEG-CS (43%
TEPB; 2.6% mPEG) derivatives would be the most efficient gene delivery vehicles due to the
high percentage of triethylphosphonium butanamide, which has been stated to improve
transfection efficiency. Moreover, I speculated that TEAB2-CS (40.6% TEAB) would be the
least effective vehicle for gene delivery due to TEAB2-CS having a high percentage of TEAB
(40.6%). Conversely, here I present that TEAB1-CS (24% TEAB), due to its low degree of
quaternization (DQ), was the most efficient gene delivery vector among all tested CS derivatives.
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MATERIALS AND METHODS

Preparation of Stock Solutions of Chitosan (CS) Derivatives
Triethylphosphonium butanamide -chitosan (TEPB-CS), Triethylammonium butanamide
-chitosan (TEAB1-CS and TEAB2-CS), Triethylammonium butanamide methoxy-poly (ethylene
glycol)-chitosan (TEAB-mPEG-CS), and Triethylphosphonium butanamide-mPEG-CS
derivatives (TEPB-mPEG-CS) were prepared with sterile 1X PBS (pH, 7.4) to make stock
solutions. TEAB1-CS (24% is the degree of quaternization with TEAB to CS) was dissolved 1X
PBS for final concentration of 2.78 mg/mL. TEAB2-CS (40.6% is the degree of quaternization
with TEAB to CS) was dissolved in 1X PBS for a total concentration of 10 mg/mL. TEPB-CS
(43% is the degree of quaternization with TEPB to CS) was dissolved in 1X PBS for a total
concentration of 5 mg/mL. TEAB-mPEG-CS (40.6% is the degree of quaternization with TEAB
to CS; 3.1% of mPEG added to TEAB) was dissolved in 1X PBS for a total concentration of 3.33
mg/mL. TEPB-mPEG-CS (43% is the degree of quaternization with TEPB to CS; 2.6% of
mPEG added to TEPB) was dissolved in 1X PBS for a concentration of 5 mg/mL.

Cell Culture
HeLa S3 cervical cancer cells plated on a 75 cm2 flask were sustained in Dulbecco
Modified Eagle Medium (DMEM) supplemented with 12% fetal bovine serum (FBS) and
antibiotics streptomycin and penicillin at 37oC in a humidified incubator with 5% CO2. After
reaching confluency, the flask was then washed twice with 10 mL 1X PBS, followed by the
addition of 3 mL of Trypsin-EDTA mixture to assist in the detachment of the cells from the
flask. The cell culture was further incubated at 37oC for 20-25 minutes for detachment from the
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plate, followed by neutralization and separation using 10 mL of DMEM. The cells were counted
using a hemocytometer to determine the appropriate amount needed for each assay listed below.

Cell Viability
Two sets of cell viability experiments were performed using an XTT assay from
Biotium. The first set was to compare the TEABs-CS, while the second set was to compare the
TEPBs-CS. HeLa cervical cancer cells served as recipients to test cell viability via the XTT
assay. These experiments were repeated twice to obtain the same results and each experiment
was performed in triplicate set. The HeLa cells were seeded on a 96 well plate with each well
containing 10,000 cells. The plate was incubated at 37oC with 5% CO2 for 24 hours in order to
adhere to the wells. The following 24 hours consisted of treatment with the chemicals.
Treatments for TEAB1-CS (24% TEAB), TEAB2-CS (40.6% TEAB), TEPB-CS (43% TEPB),
TEPB-mPEG-CS (43% TEPB; 2.6% mPEG), and TEAB-mPEG-CS (40.6% TEAB; 3.1%
mPEG) were performed with serial dilutions from 0-100 g/mL. After treatment, the cells were
incubated for another 24 hours in the same conditions listed earlier and measured using XTT.
XTT Activation Reagent, known as N-methyl dibenzopyrazine methyl sulfate or PMS, was
mixed with XTT solution for a ratio of 1:200, and 25 L of this mixture was added to each well.
The EL808 96-well spectrophotometer from Biotek was used to perform this assay, at an
absorbance value set at A450-A630nm, using the Gen5 3.03 software program to plot the cell
viability at hour 7 (Fig. 2B&C). IC50 curves below (Fig. 2D) were obtained using the IC50
calculator from AAT Bioquest. IC50 calculation was made with curves fitted according to
following equation: Y= [Min. value + (Max value-Min. value)]/[(1 + (x/IC50)Hill coefficient]. The
minimum value was set at zero. Cell viability was calculated following background substraction
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from hour zero on standard curve (Fig. 2E&F). The O.D. for non-treated control served as
standards for cells trea The following equation was used to calculate cell viability for the cells
treated with the derivatives: [O.DNTC – O.DCS/ O.DNTC] x100%.

Apoptosis
To examine the potential apoptotic effects of TEAB- and TEPB- containing chitosan
derivatives on the HeLa cells, an apoptosis assay was performed [66]. For 24 hours in the
conditions stated above, 50,000 HeLa cells were seeded on a 24-well plate. Treatments for
TEABs-CS and TEPBs-CS were performed on the same 24-well plates, with serial dilutions
ranging from 0-100 g/mL. The treatments were performed in quintuplicate sets, and cells were
grown using DMEM media supplemented with 12% fetal bovine serum (FBS) and antibiotics
streptomycin and penicillin. The treated and non-treated cells were then measured using Annexin
V-APC and propidium iodide (PI). On the day of quantitation, the cells were washed twice with
1 mL of 1X PBS, trypsinized with 0.25 mL of trypsin, and then neutralized with 0.30 mL of
DMEM supplemented with FBS and antibiotics streptomycin and penicillin. The mixture was
centrifugated at 400 x G force for 10 minutes, followed by the addition of 5 L of Annexin VAPC and 5 L of PI. The mixture was incubated for fifteen minutes and visualized using an
Attune NxT flow cytometer, and each cell was quantitated using the BL3 channel for PI and and
RL1 channel for Annexin-V APC.

Plasmid DNA (pDNA) Preparation
TPST1-EGFP plasmid was purchased from Addgene (Cat # 66617). The GFP-fused
TPST1 marks the trans-Golgi network membrane [67]. TPST1-EGFP plasmid carrying bacterial

22

strain was grown on an LB agar plate containing Kanamycin (50 µg/mL) and a single colony
transferred to TB liquid media containing 50 µg/mL Kanamycin. The plasmid DNA was purified
using a QIAprep Spin mini-prep kit purchased from Qiagen. The DNA was measured using a
Qubit dsDNA BR assay kit from Invitrogen by Thermo Fisher Scientific for a total
concentration of 186 ng/µL. Agarose gel electrophoresis using 1% agarose gel containing 0.5
µg/mL of ethidium bromide (EtBr) was used to visualize the size of the pDNA. The gel was
visualized using the Azure c300 chemiluminescent western blot imaging system from Azure
biosystems (Figure 8C).

DNA Binding Assay to Determine N+/P- and P+/P- Ratio
Agarose gel electrophoresis using 1% agaorose gel containing 0.5 µg/mL of ethidium
bromide (EtBr) was used to complex TEPB-CS (43% TEPB) with the TPST1-EGFP plasmid at
N+/P- ratios of 8:1, 4:1, 2:1, 1:1, 1:2 (Figure 8A). This same method of gel electrophoresis was
used to complex TEAB1-CS (24% TEAB) with the pDNA to determine the P+/P- ratio at which
stable polymer-DNA complex formation at the same ratios mention above (Figure 8B).

Transfection Assay
Lipofectamine LTX from Thermo-Fisher Scientific and Takara Bio’s Xfect were served
as positive controls for this assay. To quantitate the efficiency of the first twenty-four hours of
gene delivery, 100,000 HeLa cells were seeded using DMEM media unto a 24-well plate, in
order to obtain 70-90% confluency by the time of transfection, in the conditions stated above.
The following twenty-four hours the pDNA was incubated with the treatments (TEABs, TEPBs,
Lipofectamine LTX, or Xfect) in quintuplicate. The wells containing Lipofectamine or Xfect
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were incubated with 500 ng of pDNA at room temperature for 10 minutes and diluted to a
volume of 1000 µL using DMEM supplemented with 12% FBS and antibiotics, streptomycin
and penicillin. The wells treated with the CS derivatives contained a N+/P- or P+/P- (polymer:
pDNA) ratio of 10:1 and diluted to a volume of 1 mL using DMEM supplemented with 12%
FBS and antibiotics streptomycin and penicillin. All samples were incubated at 37oC with 5%
CO2 for 24 hours. On the day of quantitation, each sample was washed twice with 0.5 mL of 1X
PBS, trypsinized with 0.5 mL of trypsin-EDTA, and neutralized with 0.5 mL of DMEM media
containing 12 % FBS and streptomycin and penicillin. The mixture was centrifuged at 1500 rpm
for 10 minutes to obtain a pellet. The supernatant was discarded, and the pellet was resuspended
in 1000 µL of 1X PBS. The Attune NxT flow cytometer was used to visualize the transfected
cells using the BL1 channel, with excitation/emission wavelength set of 488/530.

Statistical Analysis
A one-way ANOVA and Dunnett’s multiple comparison test were performed using
Prism Graphpad version 8.1 to assess significance and p-values of the non-treated cells compared
to cells treated with TEAB1-CS (24% TEAB), TEAB2-CS (40.6% TEAB), TEAB-mPEG-CS
(40.6% TEAB; 3.1% mPEG), TEPB-CS (43% TEPB), and TEPB-mPEG-CS (43% TEPB; 2.6%
mPEG), Xfect, and Lipofectamine. p-values and corresponding asterisks are based on p>0.05 to
p> 0.001.

24

RESULTS

Chitosan Modified Derivative TEAB1-CS (24% TEAB) did Not Exhibit Any Cytotoxicity
Cytotoxicity of these chitosan derivatives can be a limiting factor of their ability to serve
as gene delivery agents in biological systems in vivo or in vitro. A previous study reported on the
cytotoxic effects of unmodified chitosan, upon treatment with concentrations ranging from 0-100
µg/mL. The results showed that the amount of viable BEL-7402 cells (a hepatoma cell line)
decreased in a dose dependent manner [9]. Thus, this prompted me to assess cytotoxicity effects
of the CS derivatives.
The cytotoxicity or reduction of cell viability induced by the derivatives was evaluated by
an in vitro XTT assay 7 hours after the treatment of XTT and PMS. To generate a standard
curve, known number of HeLa cells, ranging 0-10,000 cells without treating any CS derivatives,
were used to obtain A450-A630nm values (Figure 2A). Hour zero refers to the timepoint before
the addition of the activated XTT solution and hour seven is seven hours following addition of
the activated XTT solution. The standard curve also exhibits a positive control bar of 10,000
cells using RIPA buffer (Fig. 2A, far right).
The TEAB2-CS (40.6% TEAB) derivative displayed cytotoxicity at concentrations
greater than 10 µg/mL (Fig. 2B). Interestingly, the cytotoxicity experiment for TEAB1-CS (24%
TEAB) showed a dose dependent increase in cell viability when treated with 0-100 µg/mL
concentration of TEAB1-CS (24% TEAB), suggesting that TEAB1-CS (24% TEAB) positively
affects cell viability in a mild way (Fig. 2B). In contrast, the TEAB-mPEG-CS (40.6% TEAB;
3.1% mPEG) derivative reduced cell viability at 100 g/mL (Fig. 2B). At a concentration range
of 0.1-1 µg/mL TEAB2-CS (40.6% TEAB) saw a 32-64% increase in viability, but at
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concentrations greater than 10 µg/mL the viability was reduced by 40% or greater (Fig. 2, B&E)
Moreover, TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) had a 68% viability reduction at 100
µg/mL (Fig. 2, B&E) Whearas TEAB1-CS (24% TEAB) exhibited a 10-50% increase in
viability in a dose dependent manner (Fig. 2, B&E). Treatment with TEPB-CS (43% TEPB) and
TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) showed mild defects in viability from 10-100
µg/mL (Fig. 2C). The TEPB-CS (43% TEPB) derivative saw a 34-46% decrease in cell viability
in the 10-100 µg/mL range (Fig. 2, C&F). Whearas, TEPB-mPEG-CS (43% TEPB; 2.6%
mPEG) only exhibited a 37% decrease in cell viability at the concentration of 100 µg/mL (Fig. 2,
C&F). Together, all tested CS derivatives except TEAB1-CS (24% TEAB), regardless of the
presence or absence of mPEG, induced a mild defect in cell viability with higher concentration
of these derivatives.
To assess the effectiveness of CS derivatives on reducing HeLa cell viability, we
determined the half maximal inhibitory concentration (IC50). The IC50 value for TEAB-mPEGCS (40.6% TEAB; 3.1% mPEG) was 396 µg/mL, while the IC50 values TEAB2-CS (40.6%
TEAB) was 10.17 µg/mL (Fig. 2D), suggesting that of these two derivatives, TEAB-mPEG-CS
(40.6% TEAB; 3.1% mPEG) is a safer intracellular cargo delivery agent than TEAB2-CS (40.6%
TEAB). TEAB1-CS (24% TEAB)’s IC50 value was determined to be 0 because it seem to have
promoted viability, confirming that this derivative had no negative effects on HeLa cell viability
(Fig. 2D). IC50 values for TEPB-CS (43% TEPB) and TEPB-mPEG-CS (43% TEPB; 2.6%
mPEG) were not determined because they had minor to no effects on the cell’s viability. In
conclusion, both TEAB1-CS (24% TEAB) and TEPB-CS (43% TEPB) are the safest derivatives
because they do not suppress viability at all dosages used in this study (0-100 g/mL) and could
potentially be used as gene delivery agents.
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Figure 2: Chitosan derivative cytotoxicity measurements. Two separate experiments were
performed in triplicate sets A. Standard curve with optical density (O.D.) of A450-A630 was
measured at hour 0 (before the addition of XTT solution to the 96-well plate) and hour 7 after the
addition of the XTT solution. The standard curve served as reference to determine viable cells
and compare to the optical densities of the HeLa cells containing the CS derivatives; RIPA
buffer was used as a positive control. B. TEABs-CS derivatives effect on cytotoxicity. TEAB2CS (40.6% TEAB) showed defects in cell viability at concentrations higher than 10 µg/mL,
while TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) showed defects in viability at the
concentration of 100 µg/mL. Whereas TEAB1-CS (24% TEAB) showed an increase in viability.
C. TEPBs-CS derivatives effect on cytotoxicity). The TEPB treatment shows no defect in cell
viability. TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) treatment showed defects in viability at
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100 µg/mL, same as TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG). Represented by * are pvalues from 0.01 to 0.05, p-values from 0.001 to 0.01 are represented by **, and p-values from
0.0001 to 0.001 are represented by ***. D. IC50 values for TEAB derivatives: TEAB1-CS (0.0
µg/mL), TEAB2-CS (10.17µg/mL), and TEAB-mPEG-CS (396.25 µg/mL). E. Displays the
collective cell viability results of all TEAB-containing chitosan derivatives. This graph correlates
with Fig. 2B TEAB2-CS (40.6% TEAB) was more toxic to the HeLa cells above 10 µg/mL.
TEAB1-CS (24% TEAB) was not defective at any concentration and TEAB-mPEG-CS (40.6%
TEAB; 3.1% mPEG) was only defective at 100 µg/mL. F. Displays the collective cell viability
results for all TEPB-containing CS derivatives. TEPB-CS (43% TEPB) was defective at
concentrations higher than 10 µg/mL, while TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) was
defective mainly at 100 µg/mL.
Apoptosis Not Induced By TEAB1-CS
To further understand the cytotoxicity of the CS derivatives, an apoptosis assay was
performed. A previous study reported that apoptotic effects of unmodified chitosan on three
breast cancer cell lines (MDA-MB-231, MCF-7, and T47D) [66]. In light of the finding of
viability defects following treatment with concentrations of TEAB2-CS (40.6% TEAB), TEABmPEG-CS (40.6% TEAB; 3.1% mPEG), TEPB-CS (43% TEPB), and TEPBmPEG-CS, ranging
from 10-100 g/mL, I quantitatively evaluated the effect of the CS derivatives on cell apoptosis
using Annexin V-APC/PI staining. 50, 000 events were counted for each sample, and the gating
for all samples were consistent. My results only focused on viable, early apoptotic cells, and late
apoptotic cells because gating in these quadrants showed significant changes, whereas gating
from the necrosis quadrant did not exhibit significant differences from 1-100 g/mL.
No significant change can be seen in early and late apoptosis measurements after
treatment with 1 g/mL and 100 g/mL TEAB1-CS (24% TEAB). Nevertheless, at
concentration 10 g/mL there is a decrease in viable cells and an increase in apoptotic cells (Fig.
3, A-E). In contrast, dose-dependent treatment with TEAB2-CS (40.6% TEAB) led to a
significant decrease in non-apoptotic cells as the percent of early and late apoptotic cells
increases significantly (Fig. 4, A-E).
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Figure 3: TEAB1-CS (24% TEAB) apoptosis measurements. Two separate experiments were
performed in quintuplicate sets A. A representative of all five NTC flow cytometry
measurements. B. A representative of all five 1 µg/mL TEAB1-CS treated flow cytometry
measurements C. A representative of all five 10 µg/mL TEAB1-CS treated flow cytometry
measurements. D. A representative of all five 100 µg/mL TEAB1-CS treated flow cytometry
measurements. E. No significant change can be seen at all concentrations of the TEAB1-CS
treatment with viable, early, and late apoptotic cells. Represented by ns are values with p-value
>0.05, p-value from 0.01 to 0.05 is represented by *, p-value from 0.001 to 0.01 is represented
by **, and p-value from 0.0001 to 0.001 is represented by ***, and p-value<0.0001 is
represented by ****.
Treatment with 100 µg/mL TEAB2-CS (40.6% TEAB) caused a 2.3-fold increase in late
apoptosis (Fig. 4 D&E). With the same concentration of TEAB2-CS (40.6% TEAB), early
apoptotic levels increased 6-fold compared to the NTC (Fig. 4 D&E). I observed more viable
cells than apoptotic cells at the TEAB2-CS (40.6% TEAB) concentration of 1 g/mL. At
TEAB2-CS (40.6% TEAB) dosages of 10 g/mL and 100 g/mL, there were more late and early
apoptotic cells than viable cells, with more than 60% of the total cell population being either late
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or early apoptosis. Taken together, we can conclude that TEAB2-CS (40.6% TEAB) promotes
apoptosis, and therefore, it may not be an effective gene carrier for HeLa cells (Fig. 4). There are
no significant defects seen between all doses of TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG)
and the NTC, suggesting that TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) does not induce
apoptosis. Although treatment with 1 g/mL and 100 g/mL induce apoptosis, their increase
values were not statistically significant when compared to NTC (Fig. 5, A-E).

Figure 4: TEAB2-CS (40.6% TEAB) apoptosis measurements. Two separate experiments were
performed in quintuplicate sets A. A representative of all five NTC flow cytometry
measurements B. A representative of all five 1 µg/mL TEAB2-CS treated flow cytometry
measurements C. A representative of all five 10 µg/mL TEAB2-CS treated flow cytometry
measurements. D. A representative of all five 100 µg/mL TEAB2-CS treated flow cytometry
measurements. E. A 2.3-fold decrease in percentage of late apoptotic cells and 6-fold decrease in
early apoptotic cells, and a 3.11-fold decrease compared to the NTC after treatment with 100
µg/mL of TEAB2-CS. Represented by ns are values with p-value >0.05, p-value from 0.01 to
0.05 is represented by *, p-value from 0.001 to 0.01 is represented by **, and p-value from
0.0001 to 0.001 is represented by ***, and p-value<0.0001 is represented by ****.
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Figure 5: TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) apoptosis measurements. Two separate
experiments were performed in quintuplicate sets A. A representative of all five NTC flow
cytometry measurements B. A representative of all five 1 µg/mL TEAB-mPEG-CS treated flow
cytometry measurements C. A representative of all five 10 µg/mL TEAB-mPEG-CS treated flow
cytometry measurements. D. A representative of all five 100 µg/mL TEAB-mPEG-CS treated
flow cytometry measurements. E. The change between the treatments using TEAB-mPEG-CS
and the non-treated control is non-significant, because fold change from NTC to 100 µg/mL is
less than 1. Represented by ns are values with p-value >0.05, p-value from 0.01 to 0.05 is
represented by *, p-value from 0.001 to 0.01 is represented by **, and p-value from 0.0001 to
0.001 is represented by ***, and p-value<0.0001 is represented by ****.
As viable cells decrease at 1-100 µg/mL of TEPB-CS (43% TEPB), early apoptotic cells
increase after treatment with 1-100 µg/mL of TEPB-CS (Fig. 6). At a concentration of 1 g/mL
and 10 g/mL, less than 50% of the cell population were experiencing early apoptosis (Fig. 6,
B&C&E). In contrast, dosage at 100 g/mL induced early apoptosis in more than 50% of the cell
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population (Fig.6 D&E). The fold change between the non-treated control and 100 g/mL of
TEPB was a 2-fold viability decrease in the percent of viable cells and 7.25-fold increase in early
apoptotic cells (Fig. 6, A&D&E). These results are somewhat similar to TEPB-mPEG-CS (43%
TEPB; 2.6% mPEG) which significantly induced late apoptosis at concentrations of 1 to 100
µg/mL (Fig. 7, A-E). At the concentrations of 1 g/mL and 10 g/mL, less than 50% of the cell
population were late apoptotic (Fig.7, B&C&E), whilst, at the concentration at 100 g/mL late
apoptosis was induced in more than half of the cell population (Fig. 7, D&E). Concentration of
100 µg/mL TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) displayed 2.8-fold increase in late
apoptotic cells compared to the NTC (Fig. 7E).

Figure 6: TEPB-CS (43% TEPB) apoptosis measurements. Two separate experiments were
performed in quintuplicate sets A. A representative of all five NTC flow cytometry
measurements B. A representative of all five 1 µg/mL TEPB-CS treated flow cytometry
measurements C. A representative of all five 10 µg/mL TEPB-CS treated flow cytometry
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measurements. D. A representative of all five 100 µg/mL TEPB-CS treated flow cytometry
measurements. E. An increase in early apoptosis can be seen following treatment with 100
µg/mL TEPB when compared to the NTC. A 2-fold decrease in percentage of viable cells and
7.25-fold decrease in early apoptotic cells compared to the NTC after treatment with 100 µg/mL
of TEPB-CS. Represented by ns are values with p-value >0.05, p-value from 0.01 to 0.05 is
represented by *, p-value from 0.001 to 0.01 is represented by **, and p-value from 0.0001 to
0.001 is represented by ***, and p-value<0.0001 is represented by ****.

Figure 7: TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) apoptosis measurements. Two separate
experiments were performed in quintuplicate sets. A. A representative of all five NTC flow
cytometry measurements B. A representative of all five 1 µg/mL TEPB-mPEG-CS treated flow
cytometry measurements C. A representative of all five 10 µg/mL TEPB-mPEG-CS treated flow
cytometry measurements. D. A representative of all five 100 µg/mL TEPB-mPEG-CS treated
flow cytometry measurements. E. An increase in early apoptosis can be seen following treatment
with 100 µg/mL TEPB-mPEG-CS when compared to the NTC. A 1.5-fold decrease in
percentage of viable cells and 2.8-fold decrease in late apoptotic cells compared to the NTC after
treatment with 100 µg/mL of TEPB-mPEG-CS. Represented by ns are values with p-value
33

>0.05, p-value from 0.01 to 0.05 is represented by *, p-value from 0.001 to 0.01 is represented
by **, and p-value from 0.0001 to 0.001 is represented by ***, and p-value<0.0001 is
represented by ****.

Taken together, these apoptotic measurements suggest that TEAB2-CS (40.6% TEAB)
induces apoptosis, whereas TEAB1-CS (24% TEAB) and TEAB-mPEG-CS seem to have little
to no effect on cell death (Figs. 3, 4, and 5). TEPB and TEPB-mPEG-CS (43% TEPB; 2.6%
mPEG) were shown to have defects on the HeLa cells (Figs. 6 and 7), suggesting that high
concentrations of TEPB causes an increase in early apoptosis, whereas high concentrations of
TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) cause an increase in late apoptosis. Therefore,
TEAB2-CS (40.6% TEAB), TEPB-CS (43% TEPB) and TEPB-mPEG-CS induce apoptosis and
might not be effective gene delivery agents in HeLa cells.

TEAB1-CS Proved to be the Most Effective Gene Delivery Vehicle of the Five Derivatives
N+/P- ratio is the ratio between the ammonium group on chitosan and DNA phosphate
[2]. Unmodified chitosan nanoparticles with N+/P- ratio between 1CS:16 pDNA showed
efficient pDNA delivery into CHO cells [2]. The binding affinity is the confirmation of polyplex
formation. The single band as a result of TEPB-CS (43% TEPB) and pDNA polyplex formation
is at a P+/P- ratio of 4:1 (Fig. 8, A&B). However, TEAB-CS had a binding affinities at N+/Pratios of 4:1 and 8:1 on the gel (Fig. 8, A&B). We also see a band retardation in terms of
mobility as a result of a reduction in the negative charge of the CS-pDNA complex (Fig. 8,
A&B) . However, the N+/P- ratio used in my study, for all five derivatives was 10 CS
derivatives: 1 pDNA because we were not able to make more pDNA for the 4:1 ratio.
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Figure 8: Agarose gel electrophoresis for transfection assays. Each gel was performed in 1%
agarose gel containing 0.5 µg/mL of ethidium bromide (EtBr) A. TEPB derivatives P+/P- ratio.
Lanes show 8:1, 4:1, 2:1, 1:1, 1:2 ratios, and DNA alone. Ratio 4:1 was determined to be ratio at
which TEPB-DNA complexation was stable. B. TEAB derivatives N+/P- ratio. Lanes show 8:1,
4:1, 2:1, 1:1, 1:2 ratios, and DNA alone. Just like the CS derivatives containing TEPB, the ratio
of most stable TEAB-DNA conjugation was 4:1. C. Gel electrophoresis of plasmid DNA
following mini-prep. Following mini prep, pDNA concentration of186 ng/µL was used for all
transfection experiments. Both TEAB and TEPB gels showed that the ammonium and
phosphonium polyelectrolytes bound at N+/P- and P+/P- ratios of 4:1.
To investigate the effectiveness of each derivative to be used as a gene delivery vehicle,
a transfection assay was performed. TEAB1-CS exhibited the highest transfection efficiencies of
all the TEABs, while TEPB-mPEG-CS exhibited the highest transfection efficiencies of all the
TEPBs (Fig 9, A&B). The positive controls, Xfect and Lipofectamine were found to facilitate the
highest level of TPST1-EGFP gene expression at 80% ( 4.4%) and 80% ( 7.59%),
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respectively, followed by TEAB1-CS (24% TEAB) had a transfection efficiency of about 65%
( 2.72%). While TEAB2-CS (40.6% TEAB) and TEPB-CS (43% TEPB) had transfection
efficiencies of 47% ( 1.58%) and 49% ( 3.04 %), respectively.

Figure 9: TEABs and TEPBs transfection efficiency comparison. Two separate experiments were
performed in quintuplicate sets with a 24-well plate. Non-treated controls containing the naked
pDNA and the HeLa cells had 34% transfection efficiency A. Gene delivery efficiency of
TEPBs. -CS (43% TEPB) and TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) both exhibited
transfection efficiencies of 47% and 50%, respectively. B. Gene delivery efficiency of TEABs.
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TEAB1-CS (24% TEAB) displayed gene delivery efficiency of 65%. TEAB2-CS (40.6% TEAB)
and TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) displayed transfection efficiencies of 49%
and 50%, respectively. The positive controls, Xfect and Lipofectamine were found to facilitate
80% of gene expression. Represented by ns are values with p-value >0.05, p-value from 0.01 to
0.05 is represented by *, p-value from 0.001 to 0.01 is represented by **, and p-value from
0.0001 to 0.001 is represented by ***, and p-value<0.0001 is represented by ****.
TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) and TEPB-mPEG-CS exhibited
transfection efficiencies of 50% ( 1.7 %) and 50% ( 2.94 %), respectively. These results
suggest that out of the five CS derivatives, TEAB1-CS (24% TEAB) exhibited the greatest
transfection efficiency, followed by the TEPB-mPEG-CS and TEAB-mPEG-CS (40.6% TEAB;
3.1% mPEG). TEAB1-CS only showed a 19% reduction in transfection efficiency in comparison
to the positive controls, proving that chitosan derivatives with lower triethylammonium
butanamide or triethylphosphonium butanamide modifications can serve as better gene delivery
vectors than those with higher modifications.
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DISCUSSION

Cationic polymers have been widely investigated, specifically chitosan due to its many
characteristics. In this study I examined the effects of novel chitosan derivatives on viability and
as well as their ability to serve as gene delivery vectors. Here I compare my derivatives to other
commonly used non-viral synthetic polymers. I also discuss potential effects induced on the
HeLa cells by my derivatives such as anticancer effects. I also discuss how degree of
quaternization (DQ), mPEG addition, N+/P- and P+/P- ratio, quaternization using phosphonium
versus ammonium groups, and IC50 influenced the gene delivery capability of the derivatives.
My findings might contribute to future studies using non-viral vector gene therapy for genetic
diseases.

DQ Modification Affects Properties of CS
It is well known that high degrees of quaternization (DQ) of CS enhances its solubility
and can cause it to strongly attach to the cell’s plasma membrane, yet high DQ leads to
cytotoxicity and deteriorating delivery efficiency [22, 25, 68]. However, there is controversy
about the topic of DQ, especially in cancer cells. One article reported having better pDNA
transfection with high DQ of the N-(4-pyridinylmethyl) CS derivative (69% DQ) in Huh 7 cells
[69]. Another article discovered that TMC derivitives with lower DQ (30% DQ) were much safer
in HeLa cells and were better delivery agents than TMC with higher DQs (DQ of 60% and
higher) [70]. The DQ in this project ranged from 24%-43%. Furthermore, in the present study, I
report that the TEAB1-CS derivative (DQ of 24%) minutely induced apoptosis at a dosage of 10
µg/mL and had undetectable viability defects (via XTT), which I speculate might be due to the
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its low DQ (Fig. 2E and 3, C&E). Regardless of the contrasting reports by these studies, I can
assume that the effect of DQ on transfection is dependent on cell type and the specific type of
derivative used for quaternization.
Moreover, N-substitution of chitosan with alkyl group such as TEAB, TEPB, and methyl
(in the case of TMC) can lead to weakened hydrogen bonds [5]. These hydrogen bonds interact
with the negative charge on nucleic acids, which allows for more efficient delivery. An increase
in DQ leads to low DNA uptake by CS derivatives due to fewer hydrogen bonds as the amount
of quaternized amino groups on chitosan increases. Based on this, TEAB1-CS (24% TEAB)
among my five CS derivatives was the most consistent with this model. Nevertheless, as these
hydrogen bonds decrease through higher DQ, the transfection efficiency of the CS derivative
also decreases and when used to treat cells can cause defects in the cell [5]. Research has also
shown that high degrees of quaternization often decrease viability and can cause damage in the
cell such as apoptosis [22, 24, 71]. Among my four derivatives with higher DQ, TEAB-mPEGCS (DQ of 40.6%; 3.1% mPEG) is the only one that contradicts this theory because its viability
and apoptotic results do not correlate with one another (Fig. 2E & 5E. More than likely, this
opposing evidence is due to the high mPEG units in the TEAB-mPEG-CS (40.6% TEAB; 3.1%
mPEG) derivative . From this I gather that low DQ correlates with high cell viability and high
DQ correlates with high levels of apoptosis. Thus my CS derivatives prove that derivatives with
low DQ are much safer than those with high DQ.
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Addition of mPEG Units Impact Cytotoxicity: TEAB-mPEG-CS (40.6% TEAB; 3.1%
mPEG) Vs. TEPB-mPEG-CS (43% TEPB; 2.6% mPEG)
In addition to DQ, mPEG addition might have influenced toxicity. Xu et. al reported that
grafting methoxy polyethylene glycol (mPEG) units unto TMC led to an increase in solubility,
polyplex colloidal stability, and transfection efficiency and a reduction in cytotoxicity [22].
Moreover, after introduction of PEGylated 50 kDa TMC (PTMC50) and 50 kDa N-trimethyl
chitosan (TMC50) in two murine and two human cell lines, PTMC50 demonstrated better
transfection efficiency and a decrease in cytotoxicity compared to TMC50 and unmodified
chitosan [25]. The MW of the mPEG added was 5,000 kDa and thus the TEPB-mPEG-CS (43%
TEPB; 2.6% mPEG) should not have exhibited significant apoptotic effects (Fig. 7E). However,
the opposite was seen, which might have been due to a combination of two things. The first
being the low percentage (below 3%) of PEG units in TEPB-mPEG-CS (43% TEPB; 2.6%
mPEG), second being the higher modification with TEPB, which had 43% of the entire polymer
modified with the phosphonium groups. This higher modification percentage could have
contributed to TEPB-mPEG-CS (43% TEPB; 2.6% mPEG) displaying lower apoptotic effect
than TEPB-CS (Fig. 6E).
In contrast, TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG), although it’s IC50 was
396.25 g/mL, did not induce apoptotic cells. I speculate that its ammonium groups interacted
with the membrane components cell and led to the toxicity seen only at 100 g/mL. However,
because it did not induce apoptosis I can only assume that it had inhibitory effects on the
metabolism of the cancer cells. The difference in the degree of mPEG substitution between the
TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG) and TEPB-mPEG-CS (43% TEPB; 2.6% mPEG)
is very small (0.5%) and to my knowledge this percentage of mPEG substitution is actually quite
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big considering the MW of the mPEG. This difference as well as the degree to which chitosan
was modified with TEAB/TEPB groups, might have induced apoptosis (Fig. 5E and Fig. 7E).
Subsequently, it can be hypothesized that the derivatives with the high modification might be
less efficient pDNA delivery agents compared to TEAB1-CS (Fig. 9, A&B).

N+/P- Ratio Influences Transfection Efficiency
N+/P- or P+/P- ratio is a critical factor in the formation of the polyplex because it affects
the surface charge of the polyplex, the condensing ability of the DNA and the delivery of the
genetic material [15]. N+/P- ratio is the ratio between the positively charged ammonium groups
in the polymer and the negatively charged phosphate on the pDNA, whereas the P+/P- ratio is
the ratio between the phosphonium groups and the phosphate group of the pDNA [72]. High
N+/P- ratio leads to strongly formed polyplexes through electrostatic interaction, and if the bond
between the DNA and the polymer is too strong, this can prevent the nucleic acid from being
released once it arrives at its site of action [2, 28]. At lower P+/P- ratios, phosphonium-based
biopolymers bind better to nucleic acids [73] A study stated that N+/P- ratio between 1:1 and
16:1 allowed unmodified chitosan nanoparticles to efficiently deliver pDNA into the CHO cell
line [2]. The observable optimum N+/P- ratio for my ammonium CS derivatives were 8:1 and
4:1, and P+/P- ratio for my phosphonium CS derivatives was 4:1 (Fig. 8A&B). However, due to
pDNA shortage I was only able to perform the transfection assays at N+/P- and P+/P- ratios of
10:1. Although the transfection efficiency at a N+/P- or P+/P- ratio of 10:1 presented somewhat
appreciable results despite the questionable transfection efficiency results from the non-treated
controls. In conclusion a ratio of 4:1 is acceptable for both TEAB and TEPB chitosan
derivatives.
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Quaternization With Ammonium Groups Vs. Phosphonium Groups Comparing TEAB1CS (24% TEAB), TEPB-CS (43% TEPB), and TEAB2-CS (40.6% TEAB)
Quaternization of chitosan has been proven to cause an increase in cytotoxicity and
gradual inhibition of cell proliferation, but it also has led to better transfection efficiencies than
unmodified chitosan [74]. An example is seen with TMC (N-trimethyl chitosan), which has
shown promising gene delivery ability [13, 24, 25]. Furthermore, it was proven that biopolymers
substituted with ammonium groups improve chargeability of the biopolymer, which is a useful
property for gene transfection studies [24]. Modification of chitosan with quaternary ammonium
salts has also been reported to decrease toxicity, as well as promote biodegradability and
antibacterial properties [5, 24]. To my knowledge, TEAB2-CS (40.6% TEAB), exhibiting the
highest toxicity and one of the lowest transfection efficiencies might have be due the higher
TEAB modification degree on CS than TEAB1-CS (24% TEAB).
In contrast, some report that biopolymers with ammonium groups are highly toxic
compared to the those modified with phosphonium analogues. Substitution of ammonium salts
with quaternary phosphonium salts on biopolymers also allowed for increased cellular delivery
of DNA [75]. Phosphonium-substituted biopolymers exhibited increased DNA binding and gene
delivery efficiency of pDNA than ammonium-substituted biopolymers [75]. For instance, when
a triethyl-phosphonium polystyrene complex, with siRNA had better cell viability than its
ammonium equivalent [72]. However, TEPB-CS (43% TEPB) exhibited the same apoptotic
defects at all concentrations of treatment and it is unclear why this happened, because due to
charge distribution this derivative should have had the opposite effects. From this information, it
can be assumed that each derivative behaves differently in terms of its effects on the HeLa cell
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viability. It can be hypothesized from the results obtained above that low modification with
TEAB, would increase delivery efficiency and reduce cytotoxicity.

Comparing TEAB- and TEPB-Containing Chitosan Derivatives to PAMAM, PEI, and PLL
Synthetic polymers such as PEI, PAMAM (Polyamidoamine), and Poly-L-Lysine (PLL)
are oftentimes compared to chitosan, because they are much efficient at gene transfection than
chitosan. Among those three dendrimers, PAMAM is recognized as the best gene delivery
vector, however, in a clinical setting all three polymers are noticebly toxic [76]. PAMAM and
PEI are toxic to cells because they have many ammonium groups and these groups because of
their charge distribution inflict damage on the cell membrane by interacting with its components
[22, 38]. In HeLa cells, PEI was reported to have low cell viability (cell viability of 20-40%) at
concentrations ranging 5-25 μg/mL. Whereas, PAMAM had high cell viability at concentrations
lower than 100 μg/mL, which is why it is said to be one of the best polymer delivery agents [22].
On the other hand, PLL is highly toxic in HeLa cells, with cell viability as low as 50% [77].
The low cell viability results for TEAB2-CS (40.6% TEAB) and TEAB-mPEG-CS
(40.6% TEAB; 3.1% mPEG) at concentrations of 10 µg/mL and/or 100 µg/mL could have been
as a result of damage to the cell membrane as well. PEI and PAMAM induce damage to the cell
membrane because of their ammonium groups and thus results in low cell viability. Given this
information, I speculate that at least one of my derivatives (TEAB1-CS) would be safer than PEI,
PAMAM, and PLL due to its high cell viability in a dose dependent manner (Fig. 2E). However
the same cannot be said for the other two TEAB-containing derivatives that contain higher
modification with the ammonium groups. These ammonium groups might have inflicted cellular
damage which is most likely similar with to literature reports of PEI, PAMAM, and PLL [22].
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Highly modified derivatives synthetic polymers result in low transfection efficiencies,
whearas the reverse is observed with derivatives with low degrees of modification [22]. My
transfection experiments confirm this theory. Furthermore, research has shown that replacement
of ammonium groups with phosphonium moieties is safer and enhances transfection efficiency
in HeLa cells [64] [72]. However, my results conflicted with such findings, except in the case of
TEAB1-CS (24% TEAB). Transfection rates for TEPB-CS (43% TEPB) and its ammonium
analogue TEAB2-CS (40.6% TEAB) remained relatively similar, as did TEPB-mPEG-CS (43%
TEPB; 2.6% mPEG) and its counterpart TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG). The
phosphonium analog for TEAB1-CS was insoluble in PBS and thus was excluded from this
project. Although, based on these reports I speculate that if we were able to include the
phosphonium counterpart of TEAB1-CS it might have been a better gene carrier than TEAB1CS. Moreover, it has been reported that PEG addition to polymers such as PLL can increases
transfection, yet this was not the case in my study [78]. My PEG containing derivatives (TEABmPEG-CS and TEPB-mPEG-CS) displayed similar or reduced transfection efficiency compared
to their non-mPEG containing counterparts (TEAB1-, TEAB2-, and TEPB-CS). However it is
unclear why such results were seen.

IC50 Values of TEAB2-CS and TEAB-mPEG-CS Inhibited HeLa Cell Viability
IC50 is the concentration at which the HeLa cell viability is 50% inhibited.[1] Normally,
the median half maximal inhibitory (IC50) concentration value of CS derivatives ranges from 0.22.5 mg/mL in most cell models [2]. This means that the threshold at which chitosan derivatives
such as TMC inhibit cell proliferation is within 0.2-2.5 mg/mL. Whereas, my data displays IC50
values for TEAB2-CS (40.6% TEAB) and TEAB-mPEG-CS (40.6% TEAB; 3.1% mPEG)
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ranging from 0.01-0.396 mg/mL. Moreover, both both TEAB2-CS (40.6% TEAB) and TEABmPEG-CS (40.6% TEAB; 3.1% mPEG) derivatives remained belowed this threshold, thus
proving that both are more toxic than TMC (Fig. 2D).

Potential Anticancer Effect of TEAB2-CS, TEPB-mPEG-CS, and TEPB
Chitosan displays anticancer activity induced by activation of procaspase, which then
accelerates the cascades that amplify signals for cell death [79]. Once endocytosed into tumor
cells derivatives such as LMWC induces extrinsic apoptosis in which caspase 8 and cell cycle
arrest are activated, thus inhibiting tumor growth. However, tetrazolium-based tests, such as
XTT cannot differentiate between cytotoxicity or cell death which would explain why TEABmPEG had the low viability results but did not induce apoptosis [78]. Given this information, I
cannot denounce the possibility of my derivatives exhibiting anticancer activity due to the results
of my apoptosis assay. The reduction in viability at 10-100 g/mL for TEAB2-CS (40.6%
TEAB) and at 100 g/mL for TEAB-mPEG-CS could also be as a result of anticancer activity
could be induced by my derivatives (Fig. 2E, 4E, and 5E). While TEPB-CS (43% TEPB)
exhibited minor toxicity, it did extremely induce apoptosis at a concentration-dependent manner
and a possible hypothesis for this could be that TEPB-CS (43% TEPB) is able to enter the cell
without significantly harming the cell membrane, but once it is in the cytoplasm, induction of
apoptosis begins (Fig. 2F, 7E, and 6E) [71, 80]. TEAB1-CS (24% TEAB) and TEAB-mPEGCS (40.6% TEAB; 3.1% mPEG), however by exhibiting little to no apoptotic defects on the
cells, demonstrate that they both lack anti-cancer activity. I speculate that this is due to charge on
TEAB compared to TEPB groups. TEPB groups possess a more positive charge than their
ammonium analogues and this difference in charge distribution would allow for more interaction
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with negatively charged components of the cell membrane and lead to growth inhibition of the
cancer cells [72].
Several chitosan-based transfection findings in cancer models commonly transfect using
siRNA and have shown increased anticancer activity such as apoptosis signaling [80]. However,
few report anticancer activity after pDNA transfection into cancer cells. My study has shown
that anticancer activity could be induced upon addition of some of the derivatives, though this is
difficult to prove given that my derivatives were not tested on a non-cancerous cell line. I t
would be interesting to determine the specific mechanism by which the derivatives interact with
the cell when complexed to pDNA. Such results might support or denounce the anticancer claim.
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CONCLUSIONS

Here I report the safety and gene transfection efficiency of five derivatives of chitosan
modified with ammonium/phosphonium salts by using a viability assay, an apoptosis assay, and
transfection assay. Quaternization of 24% of the ammonium salt TEAB (TEAB1-CS) served as
the optimum derivative for transfection. This derivative also promoted viability at treatment
concentrations and had limited apoptotic effects in the HeLa cell line.

Limitations of the Study
My non-treated control for both transfection efficiencies showed high background
fluorescence, thus the transfection experiment would need to be replicated and the flow
cytometer would need to be adjusted in order for a more accurate representation of the
transfection efficiencies using my derivatives. Another limitation with the research was usage of
the flow cytometer before fluorescence imaging using the confocal microscopy. By first using
confocal microscopy, I would have been able to verify that the derivatives were actually able to
deliver the pDNA into the HeLa cells and then follow this up using the flow cytometer to
measure the transfection efficiency. In the future, I hope to verify the results reported here by
performing confocal microscopy in hopes of proving that my derivatives are efficient delivery
agents.

Future Directions
I originally hypothesized that the phosphonium CS derivatives would have the least
cytotoxic effects as well as promote delivery of the pDNA, in vitro, due to reports from previous
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studies comparing phosphonium-based and ammonium-based polymers.[64, 72] These studies
reported that the polymers with the phosphonium groups had high transfection efficiency and
high cell viability than the ammonium-based groups. However, in my study TEAB1-CS (24%
TEAB) was less cytotoxic and had a better transfection efficiency compared to my other
ammonium-based derivatives. In contrast, my phosphonium based CS derivatives were toxic by
inducing apoptosis and had moderate transfection efficiencies. Due to the novelty of this
research, there are currently no in-depth studies about the intercellular processes following
treatment with these chitosan derivatives. Furthermore, to understand the differences between the
phosphonium-based and ammonium-based polymers used in this study, more research needs to
be performed on how these derivatives interact with cancer cells as well as normal cells.
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